Research centres form a new Global Alliance of Leading Drug Discovery and Development Centres
Six of the world’s translational health research centres announced that they have come together to form a new Global Alliance of Leading Drug Discovery and Development Centres. The aim of this alliance is to strengthen the international academic and/or not-for-profit drug development and commercialization network to ultimately improve the rate at which academic research is translated into new medicines.
The founding organizations are:
- The Centre for Drug Research and Development (CDRD), Canada
- Lead Discovery Center (LDC), Germany
- The Scripps Research Institute, Scripps Florida, United States
- The Centre for Drug Design and Discovery (CD3), KU Leuven R&D, Belgium
- Medical Research Council Technology, United Kingdom
- Cancer Research Technology, United Kingdom
All member organizations are fully-integrated translational centres capable of advancing drug discovery projects along the value chain from idea to drug candidate with proof-of-concept. Together, they represent close to 400 experienced drug developers collaborating with tens of thousands of academic scientists around the globe on over 165 innovative therapeutic projects targeting significant unmet medical needs.
Through this Alliance, member organizations will collaborate on mutually-beneficial projects, share practices, expertise and resources, and develop common standards and performance measurements – ultimately working together to improve the conversion of global early-stage technology into much needed therapies.
Other news from the department research and development
